title: Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes.
authors.affiliation: Department of Family Medicine and Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Denise
authors.initials: D
authors.lastname: Campbell-Scherer
mesh_terms: D002318:Cardiovascular Diseases; D002319:Cardiovascular System; D003924:Diabetes Mellitus, Type 2; D004311:Double-Blind Method; D004763:Glucagon-Like Peptides; D006801:Humans; D007004:Hypoglycemic Agents; D012307:Risk Factors; D020521:Stroke; D016896:Treatment Outcome; D000099194:Semaglutide
chemical_list: D004763:Glucagon-Like Peptides; D007004:Hypoglycemic Agents; D000099194:Semaglutide